Zevra Therapeutics Inc (Zevra) formerly KemPharm Inc, s a rare disease therapeutics company that offers discovery and development of proprietary new molecular entity prodrugs. Its product portfolio include Arimoclomol, KP1077IH, KP1077N and Azstarys. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Zevra is headquartered in Florida, the US.
Headquarters
United States of America
Address
1180 Celebration Boulevard, Suite 103, Florida, 34747
Website
zevra.com
Telephone
1 321 9393416
No of Employees
65
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZVRA (NASD)
Revenue (2022)
$27.5M
170.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-72%
(2022 vs 2021)
Market Cap*
$197.6M
Net Profit Margin (2022)
XYZ
36.4%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| Arimoclomol - Orally-Delivered, First-In-Class Investigational Product Candidate for NPC |
| KP1077 - Lead Prodrug Candidate for Idiopathic IH And Narcolepsy Type I And II |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In November, the company announced the acquisition of Acer Therapeutics. |
| 2023 | Corporate Changes/Expansions | In February, the company changed its name to Zevra Therapeutics Inc. |
| 2023 | Contracts/Agreements | In January, the company entered into an agreement with Hypersomnia Foundation to promote research and advocacy for sleep disorder. |
Competitor Comparison
| Key Parameters | Zevra Therapeutics Inc | Collegium Pharmaceutical Inc | Cara Therapeutics Inc | Acura Pharmaceuticals Inc | SELLAS Life Sciences Group Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Celebration | Stoughton | Stamford | Palatine | New York |
| State/Province | Florida | Massachusetts | Connecticut | Illinois | New York |
| No. of Employees | 65 | 197 | 55 | 14 | 16 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Matthew R. Plooster | Chairman | Executive Board | 2023 | - |
| Richard W. Pascoe | Chief Executive Officer | Senior Management | 2024 | - |
| R. LaDuane Clifton | Secretary; Treasurer; Chief Financial Officer | Senior Management | 2015 | 49 |
| Adrian Quartel, M.D., FFPM | Chief Medical Officer | Senior Management | 2024 | - |
| Sven Guenther, Ph.D | Chief Scientific Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer